Clinical Trials · NCT00097500
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 69
- Start date
- Sep 2004
- Locations
- 3 sites, 3 countries
- Primary endpoint
- Beta-cell Function After 52 Weeks of Therapy